Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential

Immunovant, Inc.

2024-Q2 EPS reported -$1.01

Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.
Initial Phase 1 data for IMVT-1402 showed dose-dependent IgG reductions without significant albumin or LDL changes.
Raised ~$467M net in October 2023 public/private offering; pro forma cash $737M as of Sep 30.
Expects initial 600mg MAD cohort data for IMVT-1402 in Nov 2023; Phase 2 Graves' data by year-end 2023.
Phase 3 MG top-line data expected H2 2024; TED data H1 2025; CIDP Phase 2b data H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immunovant, Inc. reported financial results for fiscal second quarter and six months ended September 30, 2023.

Period: fiscal second quarter and six months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-23-000131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.